458 related articles for article (PubMed ID: 19608712)
1. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
3. Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.
Takizawa I; Nishiyama T; Hara N; Hoshii T; Ishizaki F; Miyashiro Y; Takahashi K
Cancer Lett; 2010 Nov; 297(2):226-30. PubMed ID: 20831980
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
6. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J
J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277
[TBL] [Abstract][Full Text] [Related]
7. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
10. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
[TBL] [Abstract][Full Text] [Related]
11. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A
J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
14. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
15. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
17. Sex steroid hormone metabolism and prostate cancer.
Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
19. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Arai S; Miyashiro Y; Shibata Y; Tomaru Y; Kobayashi M; Honma S; Suzuki K
Steroids; 2011 Feb; 76(3):301-8. PubMed ID: 21147140
[TBL] [Abstract][Full Text] [Related]
20. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]